Trade Summary

Yesterday, Van Houte Hans, serving as CFO at Nurix Therapeutics, Inc. (NRIX), sold 14,055 shares at $16.60 per share, for a total transaction value of $233,319.00. Following this transaction, Van Houte Hans now holds 37,592 shares of NRIX.

This sale represents a 27.00% decrease in Van Houte Hans's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, May 5, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, May 5, 2026, meaning the disclosure happened on the same day as the trade.

Nurix Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.